Literature DB >> 10728592

Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands.

M H Ahonen1, Y H Zhuang, R Aine, T Ylikomi, P Tuohimaa.   

Abstract

The data suggest that 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and androgens are essential for regulation of growth and differentiation in, e.g., human reproductive tissues. We investigated the possible cross-talk between 1,25(OH)2D3 and androgens in the human ovarian cancer cell line OVCAR-3. Our data demonstrate that 1,25(OH)2D3 and androgen (dihydrotestosterone, DHT) regulate the growth of OVCAR-3 cells. Nine days' treatment of OVCAR-3 cells with 100 nM DHT resulted in 48% stimulation of growth, whereas growth inhibition (73%) was observed after treatment with 100 nM 1,25(OH)2D3. The combination of 1,25(OH)2D3 and DHT showed that 1,25(OH)2D3 clearly reduces the growth-stimulatory effect of DHT on OVCAR-3 cells. Moreover, Western blot analysis revealed that these cells contain receptors for 1,25(OH)2D3 (VDR) and androgen (AR). Expression of VDR and AR was up-regulated by their cognate ligands. Up-regulation of AR by 1,25(OH)2D3 and of VDR by DHT provides evidence of cross-talk between 2 signaling pathways in OVCAR-3 cells. We also studied the immuno-histochemical distribution of VDRs and ARs in rat ovaries and human ovarian cancer cases. In rat ovaries, VDRs were observed mainly in granulosa and theca cells and ARs in granulosa cells and surface epithelium. In the human ovarian cancer cases studied, 43% were VDR-positive and 64% AR-positive. Combining the results suggests that the growth of ovarian tissue might be regulated by 1,25(OH)2D3 and androgen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728592     DOI: 10.1002/(sici)1097-0215(20000401)86:1<40::aid-ijc6>3.0.co;2-e

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.

Authors:  Erik J Tokar; Mukta M Webber
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Michael E Carney; Rachel T Palmieri; Paul D P Pharoah; Honglin Song; Estrid Hogdall; Susanne Kruger Kjaer; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Marc T Goodman
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 3.  The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms.

Authors:  Meis Moukayed; William B Grant
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

4.  The VDR gene FokI polymorphism and ovarian cancer risk.

Authors:  Hui Xu; Su Li; Jian-Qing Qiu; Xiao-Lin Gao; Ping Zhang; Yong-Xia Yang
Journal:  Tumour Biol       Date:  2013-12

5.  Sun exposure and risk of epithelial ovarian cancer.

Authors:  Clara Bodelon; Kara L Cushing-Haugen; Kristine G Wicklund; Jennifer A Doherty; Mary Anne Rossing
Journal:  Cancer Causes Control       Date:  2012-10-12       Impact factor: 2.506

6.  Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.

Authors:  Wei Zheng; Kim N Danforth; Shelley S Tworoger; Marc T Goodman; Alan A Arslan; Alpa V Patel; Marjorie L McCullough; Stephanie J Weinstein; Laurence N Kolonel; Mark P Purdue; Xiao-Ou Shu; Kirk Snyder; Emily Steplowski; Kala Visvanathan; Kai Yu; Anne Zeleniuch-Jacquotte; Yu-Tang Gao; Susan E Hankinson; Chinonye Harvey; Richard B Hayes; Brian E Henderson; Ronald L Horst; Kathy J Helzlsouer
Journal:  Am J Epidemiol       Date:  2010-06-18       Impact factor: 4.897

7.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

8.  PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.

Authors:  Mary T Galgano; Mark Conaway; Adam M Spencer; Bryce M Paschal; Henry F Frierson
Journal:  Hum Pathol       Date:  2009-05-07       Impact factor: 3.466

9.  Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies.

Authors:  Shelley S Tworoger; Margaret A Gates; Margaret A Gate; I-Min Lee; Julie E Buring; Linda Titus-Ernstoff; Daniel Cramer; Susan E Hankinson
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

Review 10.  Association between vitamin D/calcium intake and 25-hydroxyvitamin D and risk of ovarian cancer: a dose-response relationship meta-analysis.

Authors:  Jiawei Xu; Kelie Chen; Fan Zhao; Dongdong Huang; Honghe Zhang; Zhiqin Fu; Jinming Xu; Yongfeng Wu; Hui Lin; Yexinyi Zhou; Weiguo Lu; Yihua Wu; Dajing Xia
Journal:  Eur J Clin Nutr       Date:  2020-08-19       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.